Introduction
Drug metabolizing enzymes assist in the deactivation and elimination of xenobiotics from the body. On occasion, the mechanism that is in place to help deactivate foreign elements may produce a metabolite that is more or equally potent than the parent compound against a pharmacological target as with the glucuronidation of morphine to morphine 6-glucuronide against the µ-opioid receptor (Christensen and Jorgensen, 1987; Oguri et al., 1987) . In other instances, the metabolic effort to detoxify via elimination may instead produce a reactive species that can bind irreversibly to biological macromolecules to elicit organ toxicity such as with acetaminophen Mitchell et al., 1973; Potter et al., 1973) . This process known as bioactivation usually forms a reactive species with low electron density which is capable of forming an adduct with nucleophiles such as proteins (Zhou et al., 2005) . Although the progression of covalent binding leading to toxicity is unclear and under investigation, a number of enzyme systems including phase I and phase II pathways have been associated with bioactivation. Among them are cytochrome P450 (CYP) enzymes that are responsible for the metabolism of many structurally diverse compounds and are expressed in many human tissues.
It has been previously demonstrated that CYP metabolism may be coupled to Pglycoprotein (Pgp), a drug transporter (Benet and Cummins, 2001; Cummins et al., 2002; Benet et al., 2003) . The hypothesis was that Pgp may decrease the extent of CYP metabolism in the liver. Pgp is a 170 kDa protein comprising of 1280 amino acids and belongs to a superfamily of ATP binding cassette (ABC) proteins (Chen et al., 1986) . It This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on September 7, 2006 as DOI: 10.1124 at ASPET Journals on May 27, 2017 dmd.aspetjournals.org Downloaded from is expressed in cancerous as well as non-cancerous tissues such as the brush border membrane of the intestine, liver and kidney and the blood-brain barrier (Silverman and Schrenk, 1997 whereas studies in non-cancerous tissues have shown that the efflux properties of Pgp prevent foreign elements from crossing the Pgp barrier (Xie et al., 1999; Lee et al., 2000; Mahar Doan et al., 2002; Wang et al., 2004 ).
There are several arguments that can be made for the relationship that exists between CYP and Pgp activity including overlap of substrate specificities, common tissue localization and coinducibility (Cummins et al., 2002) . In addition, CYP and Pgp serve a similar purpose which is detoxification and elimination. Consequently, if Pgp is able to indirectly alter CYP activity, the extent of drug bioacivation may also be modified by drug transporters for compounds that are substrates for both CYP and Pgp. Therefore, by limiting the access of a compound for metabolism through efflux, Pgp may help attenuate adverse reactions caused by reactive intermediates. Pgp may decrease bioactivation by several means. One is that Pgp may prevent access to certain systems such as with the blood brain barrier (BBB). It has been mentioned that one probable reason why the Pgp substrate loperamide does not elicit neurotoxicity is because it is denied access to the BBB (Kalgutkar and Nguyen, 2004) . Another possibility is that Pgp may be able to quickly remove the xenobiotic before it has a chance to interact with the metabolizing enzymes in the liver by excreting it into the bile.
This article has not been copyedited and formatted. The final version may differ from this version. The goal of this paper was to study the contribution of Pgp on the bioactivation of naphthalene and raloxifene in cryopreserved and freshly isolated human hepatocytes.
Mechanism of bioactivation for both compounds has been proposed earlier by other laboratories and is illustrated in Figure 1 . Naphthalene is not a substrate for Pgp and its bioactivation is hypothesized to be the formation of an epoxide and quinone that is mediated by CYP1A, CYP3A and CYP2E1 (Tingle et al., 1993; Gram, 1997) .
Raloxifene, or Evista ®, is selective estrogen receptor modulator marketed for the treatment of osteoporosis which can attain peak plasma concentrations of 1 nM in human (Hardman et al., 2001) . It is a substrate for Pgp (Jeong et al., 2004 ) and its bioactivation is hypothesized to be mediated mainly by CYP3A4 (Chen et al., 2002) . To measure the extent of bioactivation, irreversible binding of the reactive intermediate metabolites to
proteins and the formation of raloxifene-GSH adducts were determined. By using specific inhibitors for Pgp (verapamil) and CYPs (ketoconazole for CYP3A and 4-methylprayzole for CYP2E), changes in the covalent binding and GSH adducts were monitored to investigate into the roles of Pgp and CYP enzymes in drug bioactivation.
This article has not been copyedited and formatted. The final version may differ from this version. Control reactions were run in the absence of NADPH or in the presence of 10 mM GSH.
All reactions were performed in triplicates. final incubation concentration of 10 µM with or without various inhibitors for Pgp (1 to 500 µM verapamil), CYP3A (0.05 to 1 µM ketoconazole) or CYP2E (10 to 5000 µM 4-methylpyrazole). The reaction was stopped with 400 µL acetone after 2 hour incubation.
The precipitated proteins were recovered using the above method outlined for microsomes. Hepatocyte covalent binding calculations were based on a protein content of 1.7 mg/million cells.
Intracellular Raloxifene-GSH Levels in Hepatocytes. 2 mL of cryopreserved hepatocytes
were preincubated for 5-10 minutes. Raloxifene (10 µM) was then incubated for 2 hr in the hepatocytes with either verapamil (100 µM), ketoconazole (1 µM) or methanol (control). The reaction was stopped with 2 mL of methanol. The reaction mixture was centrifuged at 3000g for 10 minutes and dried down with nitrogen. 200 µL acetonitrile containing reserpine, as an internal standard, was used to reconstitute the reaction mixture. 50-100 µL were injected onto a Thermo-Finnigan TSQ Quantum Ultra mass spectrometer equipped with Agilent 1100 LC-pumps and a CTC-PAL autosampler.
Chromatographic conditions were adopted from Chen et al. with modifications (Chen et This article has not been copyedited and formatted. The final version may differ from this version. in acetonitrile) were pumped through a Zorbax Rx-C8 (4.6mm x 25cm) column (Agilent Technologies, Palo Alto, CA) at a flow rate of 1 mL/min starting with a 7 minute isocratic hold at 10% B followed by a 8 minute linear gradient to 20% B. After a 7
minute isocratic hold at 20% B, there was a 5 minute linear gradient to 30% B.
Following an isocratic hold for 5 minutes at 30% B, there was a 8 minute linear gradient to 95% B. Followed an isocratic hold for 2 minutes, there was a 4 minute linear gradient to 10% B. This was followed by a 4 minute isocratic hold at 90% B for column equilibration. Raloxifene, the raloxifene-GSH adducts, and reserpine (internal standard)
were monitored in the single reaction monitoring ( of raloxifene-GSH adducts were not available, the peak areas were integrated and the ratios of GSH-adduct peak area to internal standard peak area were calculated and compared between each sample. Since the highest amount of raloxifene-GSH adduct formed was not greater than 500 pmol drug equivalent/mg protein, it was assumed that the detector response was linear across the concentration range of GSH-adducts formed.
This article has not been copyedited and formatted. The final version may differ from this version. mediated. These data support previous claims that bioactivation for raloxifene and naphthalene is P450 mediated. In the presence of GSH, the covalent binding attenuated to 92 + 11 and 35 + 4 pmol drug equivalent/mg protein with raloxifene and naphthalene, respectively.
The effect of CYP and Pgp inhibitors on covalent binding of raloxifene and naphthalene were also examined in microsomes. Ketoconazole is a potent CYP3A inhibitor which can attain peak plasma concentrations of 3.2 µM in human (Hardman et al., 2001 Verapamil is a potent inhibitor of Pgp which can attain peak plasma concentrations of 600 nM in human (Hardman et al., 2001) . Various concentrations of verapamil were coincubated with either raloxifene or naphthalene to determine the effect of verapamil on covalent binding. Table 1 show that the Pgp inhibitor had no effect on the covalent binding of either compounds examined.
Covalent Binding in Hepatocytes. Covalent binding was examined in three separate lots of freshly isolated human hepatocytes. Both raloxifene and naphthalene exhibited measurable covalent binding at 82.3 + 22.9 and 210 + 43 pmol drug equivalent/mg protein, respectively. As summarized in Table 2 , data show that ketoconazole significantly decreased (p<0.005) the covalent binding of raloxifene. However, consistent with the microsome data, only 4-methylpyrazole, and not ketoconazole, significantly decreased (p<0.005) the covalent binding of naphthalene. In the presence of verapamil, the covalent binding of raloxifene significantly increased (p<0.005).
However, verapamil had no effect on the non-Pgp substrate naphthalene.
Cryopreserved human hepatocytes pooled from 5 donors were also employed to examine the covalent binding of raloxifene. As listed in Table 3 
Discussion
There are several defense mechanisms that the body has created to prevent foreign molecules from reaching their intended target. One mechanism is the enzymatic conversion of the intruding molecules to more hydrophilic moieties mediated by drug metabolizing enzymes such as CYPs. These metabolites may undergo further metabolism by means of conjugation which helps facilitate elimination through excretion into the urine or the bile. CYPs have broad substrate specificities and are almost ubiquitously distributed with high expression in the liver and the intestine ensuring that the drug is quickly and efficiently eliminated. However, despite the efforts for detoxification, some compounds may become bioactivated to produce chemically reactive intermediates that can irreversibly bind to DNA or proteins. Once these macromolecules become altered, toxicity may ensue from loss of activity or trigger an auto-immune response.
Another defense mechanism is the plasma membrane that surrounds the cells. In addition to providing a physical barrier, it may express efflux drug transporters such as Pgp to actively prevent access of drugs. When neighboring cells form tight junctions, a protective partition is formed to thwart unwanted intrusions as observed with the BBB and the intestine. Previously, it has been put forward that drug transporters may modulate metabolism (Benet and Cummins, 2001; Cummins et al., 2002; Johnson et al., 2003) . It has been hypothesized that if a compound is a substrate for both drug transporter and drug metabolizing enzyme, the access of the particular compound to the enzyme may be determined by the transporter. Therefore, in the liver where the Pgp This article has not been copyedited and formatted. The final version may differ from this version. creates a gradient favoring excretion into the bile, the extent of metabolism of a Pgp substrate may be lower than for a non-Pgp substrate. Since the liver is one of the primary sites for metabolism and bioactivation, this work aims to examine the role of Pgp in the bioactivation of a Pgp substrate and a non-Pgp substrate using human hepatocytes.
Covalent binding was employed as a tool in an attempt to measure the extent of bioactivation.
It has been previously shown that raloxifene is a substrate for drug transporters including Pgp and MRP (Jeong et al., 2004) , whereas naphthalene is not a substrate for active efflux transporters. If the process of bioactivation is coupled with Pgp, the extent of covalent binding is expected to increase for Pgp substrates in the presence of verapamil because as Pgp becomes blocked, the opportunity for the Pgp substrate to interact with the enzyme to form reactive intermediates increases. Verapamil is commonly utilized to block Pgp. In the presence of verapamil, the covalent binding of raloxifene in freshly isolated hepatocytes was significantly higher than when compared with no inhibitor.
Contrarily, verapamil had no effect on the covalent binding of the non-Pgp substrate naphthalene. These data summarized in Table 2 should have no effect in the microsomes. As it turns out, the extent of covalent binding was not altered in microsomes for both raloxifene and naphthalene as shown in Table 1 .
Although verapamil is oftentimes used as a potent inhibitor of Pgp, it has also been connected with the inhibition of testosterone 6β-hydroxylation (Yeo and Yeo, 2001 ), a marker for CYP3A4 activity. However, the mechanism for inhibition was time-dependent and greater than 50% inhibition was only observed when it was preincubated for at least 25 minutes. Furthermore, the IC 50 values of testosterone 6β-hydroxylation were 9-fold lower when preincubated compared to coincubation conditions. As outlined in the One alternate explanation as to how verapamil may be increasing the covalent binding of raloxifene may be that it has been linked to GSH depletion. It has been previously demonstrated that 100 µM verapamil may be able to stimulate MRP1 mediated efflux of GSH (Loe et al., 2000) . Therefore, if GSH is completely depleted, the reactive intermediates would be more available to bind irreversibly to macromolecules. There are several reasons why GSH depletion cannot be the reason for increased covalent binding it is unlikely that GSH would be completely depleted in the hepatocytes. Second, if GSH depletion resulted in the increase covalent binding of raloxifene, the covalent binding for naphthalene should have increased as well. However, Table 2 shows that the covalent binding of naphthalene was not affected in the presence of verapamil. Finally, Figure 2 shows that in the presence of verapamil, the amount of raloxifene-GSH adduct increased when compared to the control lacking verapamil. The increase with verapamil is consistent with this paper's hypothesis that Pgp may modulate bioactivation. By blocking Pgp, the metabolism, and therefore bioactivation, is increased as more raloxifene is able to interact with the enzyme.
Blocking metabolism decreases bioactivation and thus, the extent of covalent binding is expected to decrease. The mechanism of bioactivation for raloxifene and naphthalene is illustrated in Figure 1 . The mechanism proposed for raloxifene bioactivation is the formation of arene oxides or a quinone mediated by CYP3A4 (Chen et al., 2002) . The mechanism proposed for naphthalene bioactivation is the formation of the 1,2-epoxide mediated by CYP1A2, CYP3A4 and CYP2E1, followed by the formation of quinones mediated by CYP1A2 and CYP3A4 (Wilson et al., 1996) . However, the formation of 1-naphthol, which is an intermediate to the formation of the quinones, is not mediated by P450s but mediated by spontaneous chemical rearrangement (Jerina et al., 1970) .
This article has not been copyedited and formatted. The final version may differ from this version. The extent of covalent binding was examined in the presence of 1 µM ketoconazole. In incubations with microsomes (Table 1) and hepatocytes (Table 2) , raloxifene covalent binding decreased as expected. Interestingly however, ketoconazole was not able to change naphthalene covalent binding (Table 1 and Table 3 ). Instead, 500 µM 4-methylpyrazole, an inhibitor for CYP2E1, significantly decreased the covalent binding of naphthalene. Although more follow-up studies are needed, these data with naphthalene suggest that CYP2E1 may play a major role in naphthalene bioactivation and that 1,2-epoxide may be the critical intermediate in eliciting irreversible binding.
Covalent binding was examined in pooled cryopreserved human hepatocytes (Table 3) .
Although there may be damage associated with the freeze-thaw cycles of cryopreserved cells, studies have shown that CYP activities are well intact (Li et al., 1999) .
Consequently, raloxifene covalent binding significantly decreased in the presence of ketoconazole. Additionally, it has been shown that uptake transporters involved in the movement of taurocholate and estradiol 17β-glucuronide were functioning in cyropreserved hepatocytes (Shitara et al., 2003 
Legend
Figure 1. Proposed mechanism of bioactivation for raloxifene (Chen et al., 2002) and naphthalene (Wilson et al., 1996) . Bioactivation of raloxifene has been hypothesized to be mediated by the formation of arene oxide or quinone intermediate via CYP3A4.
Bioactivation of naphthalene has been hypothesized to be mediated by the formation of 1,2-epoxide and/or quinones. Data examined in this paper suggest that the formation of 1,2-epoxide via CYP2E1 may be the major cause of irreversible binding of naphthalene. This article has not been copyedited and formatted. The final version may differ from this version. 
